CG-SpikeDown
/ Caregen
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 22, 2022
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Volunteers of the Novel Self-Administered Intranasal CG- SpikeDown Antiviral Drug
(clinicaltrials.gov)
- P1 | N=16 | Not yet recruiting | Sponsor: Caregen Co. Ltd. | Phase classification: P1/2 ➔ P1 | N=60 ➔ 16 | Trial completion date: May 2023 ➔ Jan 2023 | Initiation date: May 2022 ➔ Oct 2022 | Trial primary completion date: May 2022 ➔ Jan 2023
Enrollment change • Phase classification • Trial completion date • Trial initiation date • Trial primary completion date
1 to 1
Of
1
Go to page
1